LOUISVILLE, CO, September 11, 2024 – AmideBio, LLC, a privately-held biopharmaceutical company, announced today that it has received $1.93M in funding through a Direct-to-Phase 2 Small Business  Innovation Research (SBIR) grant from the National Institute of Diabetes and Digestive and Kidney  Diseases (NIDDK). The grant will allow AmideBio to develop a dual agonist insulin for treating diabetics  with impaired awareness of hypoglycemia. The Company has already developed several lead candidates  with potent in vivo activity suitable for further study and this funding will provide the resources necessary  to finalize the selection of a drug candidate to bring forward to an Investigational New Drug (IND)  application in preparation for the first clinical trial for safely addressing IAH.  

“This grant will enable us to bring forward a dual agonist insulin-glucagon biologic to clinical readiness  with a time-action profile similar to regular insulin but without the risk of hypoglycemia if an overdose  occurs,” said Pawel Fludzinski, CEO and President of AmideBio. “We are grateful the NIDDK has agreed to  fund the development of a what will in essence be a molecular artificial pancreas system (mAPS) with the  potential to reduce the risk of IAH for people living with diabetes”. 

About IAH 

IAH is defined as reduced ability to recognize or perceive the onset of hypoglycemia, meaning that  hypoglycemia symptoms are not triggered until glucose levels are very low, often after cognitive function  is impaired. IAH affects 20–25% of people living with type 1 diabetes and 10% of people with type 2  diabetes treated with insulin therapy. Owing to the reduced ability to recognize hypoglycemia and take  corrective action, IAH is a major risk factor for severe hypoglycemia. This occurs when blood glucose falls  so low that the person is unable to self-treat the hypoglycemia and/or experiences loss of consciousness  or seizure, requiring third-party intervention.  

About AmideBio: 

AmideBio has a pipeline of novel biotherapeutics targeting metabolic diseases. This pipeline was  generated by leveraging its core competencies in intelligent design of drug candidates together with its  proprietary BioPure™ technology which delivers difficult-to-manufacture peptides of any length with  unprecedented purity for the pharmaceutical and biotech industry.

Contact:

Pawel Fludzinski, PhD
CEO & President
T: (505) 469-8466
pawel.fludzinski@amidebio.com